However, the hormone receptor-positive HER2-negative/low (HR+HER2−) subtype is still the most common subtype in IBC patients, as it is common in non-IBC patients; however, unlike non-IBC patients, HR + IBC is not associated with an indolent course or favorable outcomes [5–8]. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.